Endologix, Inc. (NASDAQ:ELGX) Position Raised by Vanguard Group Inc.
Vanguard Group Inc. boosted its stake in shares of Endologix, Inc. (NASDAQ:ELGX) by 5.1% during the first quarter, Holdings Channel reports. The fund owned 6,285,069 shares of the medical instruments supplier’s stock after buying an additional 306,397 shares during the period. Vanguard Group Inc. owned about 0.08% of Endologix worth $45,505,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in ELGX. Quantbot Technologies LP bought a new position in Endologix during the first quarter valued at $160,000. Emerald Advisers Inc. PA bought a new position in Endologix during the first quarter valued at $222,000. Quantitative Systematic Strategies LLC bought a new position in Endologix during the first quarter valued at $261,000. MARSHALL WACE ASIA Ltd bought a new position in Endologix during the first quarter valued at $323,000. Finally, Marshall Wace North America L.P. bought a new position in Endologix during the first quarter valued at $323,000.
Shares of Endologix, Inc. (NASDAQ:ELGX) traded up 2.64% during trading on Friday, hitting $4.28. 680,231 shares of the company’s stock were exchanged. The company has a 50-day moving average of $4.82 and a 200-day moving average of $5.96. Endologix, Inc. has a 12-month low of $4.08 and a 12-month high of $13.30. The company’s market cap is $357.10 million.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The firm had revenue of $48.60 million during the quarter, compared to analyst estimates of $47.58 million. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. Endologix’s quarterly revenue was down 4.6% on a year-over-year basis. On average, equities analysts expect that Endologix, Inc. will post ($0.62) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Endologix, Inc. (NASDAQ:ELGX) Position Raised by Vanguard Group Inc.” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/endologix-inc-nasdaqelgx-position-raised-by-vanguard-group-inc.html.
Several research firms recently weighed in on ELGX. BidaskClub cut shares of Endologix from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Canaccord Genuity reaffirmed a “hold” rating on shares of Endologix in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 target price on shares of Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a “hold” rating in a research note on Wednesday, August 2nd. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 target price on shares of Endologix in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating and eleven have issued a hold rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $6.28.
In related news, Director Dan Lemaitre bought 22,522 shares of the stock in a transaction on Monday, May 22nd. The stock was bought at an average price of $4.43 per share, with a total value of $99,772.46. Following the completion of the purchase, the director now directly owns 68,689 shares in the company, valued at approximately $304,292.27. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guido J. Neels bought 20,000 shares of the stock in a transaction on Friday, May 19th. The shares were bought at an average cost of $4.32 per share, with a total value of $86,400.00. Following the purchase, the director now owns 61,380 shares of the company’s stock, valued at $265,161.60. The disclosure for this purchase can be found here. Insiders purchased 44,722 shares of company stock valued at $195,676 in the last three months. 3.90% of the stock is currently owned by insiders.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.